PER-068-01已完成未知
CLINICAL PROTOCOL OF A RANDOMIZED, DOUBLE-BLIND STUDY, PLACEBO CONTROLLED IN PARALLEL GROUPS, TO COMPARE THE VALDECOXIB ANALGESIC ACTIVITY (SC-65872) 40 MG, TWICE A DAY IN PATIENTS WITH CHRONIC PAIN BY CANCER
PHARMACIA & UPJOHN INTERAMERICAN CORPORATION,0 个研究点目标入组 0 人开始时间: 2001年10月22日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 0（—）
入选标准
- •The patient must have the legal age to grant consent, or be older than that age.
- •The patient has chronic pain related to cancer or as a result of previous cancer therapy, which is expected to last at least 6 weeks. The main component of pain should be visceral and / or somatic-based nociceptive pain and require daily analgesic medication during the 6-week study period.
- •The patient must be in a Level II or lower on the WHO analgesic scale.
- •The patient has pain related to cancer or as a result of a previous oncological therapy whose measurement of the worst intensity is> 2, using the 11-Point Numerical Rating Scale (NRS), in five of the seven days prior to the Visit of Selection.
- •The patient has an average pain intensity> 2, using the 11-point Numerical Rating Scale (NRS), for 3 consecutive days before the baseline visit.
- •If you use an opioid combination product, the daily dose in oral morphine equivalents is <40 mg.
- •The patient´s weight is> 50 kg.
- •The patient presents a Kamofsky Performance Score> 70 at the baseline
- •The patient has an expectation of life> 6 months from the beginning of the study.
- •The female patient is postmenopausal, surgically sterile, or uses an adequate method of contraception, is not breastfeeding or nursing a baby, and presented a negative pregnancy test in serum within 14 days before starting the study.
- •The patient provided written informed consent prior to performing any procedure related to the study.
排除标准
- •Those patients whose pain is classified mainly as neuropathic or of unknown nature.
- •Those patients whose daily opioid combination requirements in oral morphine equivalents are> 40 mg / day and / or receive a prolonged-release (SR) formulation.
- •Patients currently participating in a research chemotherapy trial.
- •Those patients who foresee the initiation of the use of the new chemotherapeutic agent in less than three weeks before the first dose or during the first 2 weeks of the study.
- •Patients who are using active oncological therapy within two weeks before randomization until week 2 of the study, therapy that could be thought to confuse the evaluation of analgesic efficacy or safety of the study drug.
- •Those patients who are scheduled to undergo a therapeutic procedure (for example, surgery or biopsy), likely to influence their pain intensity until week 2 of the study.
- •The reception of radiopharmaceutical treatment or radiotherapy within 4 weeks of randomization, until week 2 of the study.
- •Initiation of a bisphosphonate treatment within 8 weeks of randomization until week 2 of the study. Patients who have started bisphosphonate therapy> 8 weeks before randomization can continue using bisphosphonates according to the instructions received.
- •The patient received any agent under investigation within 30 days prior to the first dose of the study medication or is scheduled to receive a drug under investigation other than valdecoxib during the course of this study.
- •History of esophageal or gastric cancer.
- •Patients with AIDS or cancers related to AIDS.
- •Mild to moderate hepatic insufficiency.
- •Those patients who have been diagnosed or have received treatment for esophageal, gastric, pyloric or duodenal channel ulceration, within 30 days prior to receiving the first dose of the study medication.
- •Known renal insufficiency, and / or creatinine level> 1.5 mg / dl.
- •Platelet count <40,000, or impaired platelet function.
- •Presence or history of a disease or unstable condition that, in the opinion of the investigator, would exclude the participation of the patient in the trial.
- •Inability to take tablets or tolerate oral medication.
- •Intractable nausea and vomiting.
- •History of hypersensitivity to cyclooxygenase inhibitors (DAINEs, specific inhibitors of COX-2) or opioids.
- •History of significant abuse of alcohol, analgesics, or narcotic substances within six months prior to the Selection.
研究者
相似试验
招募中
4 期
STUDY OF COMPARING CHANGES IN VITALS AND INTRAOCULAR PRESSURE OF ETOMIDATE AND MIDAZOLAM IN PATIENTS OF HYPERTENSION AND CORONARY ARTERY DISEASE UNDERGOING CATARACT SURGERY DURING CONSCIOUS SEDATIOCTRI/2016/11/007429SIR TAKHTSINHJI HOSPITA60
已完成
不适用
REVISED CLINICAL PROTOCOL FOR A RANDOMIZED, DOUBLE-BLIND, CONTROLLED BY PLACEBO, STUDY TO COMPARE THE ANALGESIC ACTIVITY OF VALDECOXIB (SC-65872) 40 MG TWICE PER DAY AS ADDITIVE MEDICATION THERAPY OPIATES IN PATIENTS WITH CHRONIC CANCER PAI-R522 Other chronic painOther chronic painR522PER-058-01PHARMACIA & UPJOHN INTERAMERICAN CORPORATION,
进行中（未招募）
1 期
A clinical trial for a guided early administration of antibiotics for presumed infection at the EREUCTR2018-001008-13-GRHELLENIC INSTITUTE FOR THE STUDY OF SEPSIS220
招募中
Unknown
A Prospective, Comparative Clinical Study of Two Sedatives for Patients Needing Invasive Breathing Support (Ventilator) in ICCTRI/2023/03/051210one
已完成
不适用
Clinical Protocol For a Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Celecoxib (SC-58635) In The Prevention of Colorectal Sporadic Adenomatous Polyps (PRESAP)-C18 Malignant neoplasm of colonMalignant neoplasm of colonC18PER-069-01PHARMACIA & UPJOHN INTERAMERICAN CORPORATION,